» Articles » PMID: 19956499

Co-expression of Cox-2, C-met and Beta-catenin in Cells Forming Invasive Front of Gallbladder Cancer

Overview
Specialty Oncology
Date 2009 Dec 4
PMID 19956499
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Gallbladder cancer is a malignancy with poor prognosis, predominantly resulting from invasion and metastasis. Our previous studies have demonstrated that prostaglandin E(2) (PGE(2)), generated by cyclooxygenase 2 (Cox-2), transactivates epidermal growth factor receptor (EGFR), c-Met and beta-catenin; thus, enhancing colon cancer cell growth and invasiveness in vitro. To determine whether these findings are applicable to clinical conditions, we examined the expression and cellular localization/co-localization of Cox-2, c-Met, beta-catenin, EGFR and c-erbB2 in gallbladder cancer.

Materials And Methods: Thirty-five specimens of invasive gallbladder cancer, 8 in situ carcinoma and 7 adenoma specimens were immunostained with specific antibodies against Cox-2, c-Met, beta-catenin, EGFR and c-erbB2. The cellular distribution, localization and colocalization were examined, and the signal intensities quantified in: a) the central area of gallbladder cancer and b) cancer cells forming the invasive front.

Results: Cox-2, c-Met, beta-catenin, c-erbB2 and EGFR were over-expressed in 80, 74, 71, 62 and 11% of invasive gallbladder cancers, respectively. beta-catenin was expressed in 80% of non-malignant specimens, exclusively in the cell membrane, while the cancer specimens showed cytoplasmic and/or nuclear staining. Significantly higher Cox-2, c-Met and beta-catenin expressions were present in cancer cells of the invasive front than in the tumor central areas (p<0.001), and these expressions were significantly (p=0.01) associated with the invasion depth. Co-expressions of Cox-2, c-Met, beta-catenin and c-erbB2 were present in 42% of the specimens in cancer cells forming the invasive front.

Conclusion: The overexpressions, and often co-localizations, of Cox-2, c-Met and beta-catenin in cancer cells forming the invasive front indicate their local interactions and important roles in invasion.

Citing Articles

Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers.

Lu W, Aihaiti A, Abudukeranmu P, Liu Y, Gao H Mol Cell Biochem. 2024; 480(2):1225-1239.

PMID: 38963615 DOI: 10.1007/s11010-024-05057-2.


EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.

Kim Y, Jee S, Kim H, Paik S, Choi D, Yoo S Oncologist. 2024; 29(8):e1051-e1060.

PMID: 38709907 PMC: 11299936. DOI: 10.1093/oncolo/oyae076.


Krukenberg Tumor Related to Gallbladder Cancer in a Young Woman: A Case Report and Review of the Literature.

Grizzi G, Ghidini M, Ratti M, DErcole M, Tanzi G, Abbiati A J Pers Med. 2023; 13(6).

PMID: 37373946 PMC: 10304896. DOI: 10.3390/jpm13060957.


Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.

Sturm N, Schuhbaur J, Huttner F, Perkhofer L, Ettrich T Cancers (Basel). 2022; 14(22).

PMID: 36428670 PMC: 9688543. DOI: 10.3390/cancers14225580.


Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway.

Neogi K, Murumkar P, Sharma P, Yadav P, Tewari M, Karunagaran D Transl Oncol. 2022; 19:101395.

PMID: 35325837 PMC: 8938628. DOI: 10.1016/j.tranon.2022.101395.


References
1.
Prigent S, Lemoine N . The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 1992; 4(1):1-24. DOI: 10.1016/0955-2235(92)90002-y. View

2.
Eberhart C, Coffey R, Radhika A, Giardiello F, Ferrenbach S, DuBois R . Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107(4):1183-8. DOI: 10.1016/0016-5085(94)90246-1. View

3.
Danilkovitch-Miagkova A, Zbar B . Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002; 109(7):863-7. PMC: 150937. DOI: 10.1172/JCI15418. View

4.
Shirahama T, ARIMA J, Akiba S, Sakakura C . Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer. 2001; 92(1):188-93. DOI: 10.1002/1097-0142(20010701)92:1<188::aid-cncr1308>3.0.co;2-w. View

5.
Pai R, Soreghan B, Szabo I, Pavelka M, Baatar D, Tarnawski A . Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002; 8(3):289-93. DOI: 10.1038/nm0302-289. View